GlassScriptPhysician profile
Heather A Weber
NPI 1013094994
$3,479.22
in general payments reported to CMS, 2019-2025
34 companies · $650 in 2025
The $650 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,944 · 2022: $255 · 2023: $411 · 2024: $218 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $388.72 | 2021 | |
| Lilly USA, LLC | $354.78 | 2021-2023 | Mounjaro |
| Abbott Laboratories | $335.44 | 2021-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $311.83 | 2021-2025 | Korlym |
| Amgen INC. | $301.12 | 2021-2025 | Repatha |
| Glaxosmithkline, LLC. | $218.28 | 2021-2023 | Arexvy, Shingrix |
| Pfizer INC. | $210.59 | 2021-2024 | |
| Novo Nordisk INC | $153.56 | 2021 | |
| Exact Sciences Corporation | $132.77 | 2023-2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $128.65 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.93 | 2021 | |
| Echosens North America, INC. | $117.49 | 2025 | Fibroscan |
| Astrazeneca Pharmaceuticals LP | $86.04 | 2021 | |
| Dexcom, INC. | $76.73 | 2021-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $62.22 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $54.45 | 2021 | |
| Esperion Therapeutics, INC. | $46.74 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.56 | 2021 | |
| Jazz Pharmaceuticals INC. | $43.14 | 2021 | |
| Eisai INC. | $33.93 | 2021 | |
| Currax Pharmaceuticals LLC | $30.50 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $29.92 | 2021 | |
| Amarin Pharma, INC. | $26.81 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.14 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.96 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.24 | 2021 | |
| Medtronic, INC. | $15.26 | 2021 | |
| Electromed, INC. | $14.66 | 2024 | Smartvest |
| Supernus Pharmaceuticals, INC. | $14.15 | 2021 | |
| Bioventus LLC | $13.98 | 2022 | |
| Dynavax Technologies Corporation | $13.35 | 2024 | Heplisav-B |
| Astellas Pharma US INC | $13.00 | 2021 | |
| Adlon Therapeutics L.P. | $11.88 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.